Eisai's IQLIK Moment: Subcutaneous Shift Unlocks Alzheimer's Growth
Strong H1 results mask a conservative guidance stance as LEQEMBI's auto-injector drives unprecedented uptake and sets up a 2027 Medicare Part D catalyst.
4523.T · Earnings Call · 2026-11-10
The IQLIK Inflection
Eisai's Q2 FY2026 earnings call was a coming-out party for LEQEMBI IQLIK, the subcutaneous auto-injector formulation of lecanemab. Management reported that since the August launch for initiation treatment, patient uptake has been roughly four times faster than the IV formulation, and the number of prescribers has grown six times faster. The auto injector is not just a convenience upgrade; it is dismantling the infusion-capacity bottleneck that had constrained the franchise. As CEO Haruo Naito put it, “the hurdle for the treatment has been lowered, and therefore, uptake in the market has been very strong.” — Haruo Naito, Chief Executive Officer (CEO) · 2026-11-10 Katsuya Haruna, Head of Global LEQEMBI Business, added that weekly IQLIK sales have increased week after week, with the formulation now approaching 10% of total LEQEMBI net sales.This is a stark reversal from prior quarters when infusion capacity was the dominant concern. In the Q4 FY2024 call, infusion capacity was the top keyword with a massive momentum score, reflecting the struggle to secure chairs and beds for IV infusions. By the May 2025 call, Haruna could say “the infusion chairs, I believe that the -- that issue or challenge has been resolved.” — Katsuya Haruna, Executive Officer, responsible for US and Japan business (LEQEMBI) · 2025-05-15 Now, with IQLIK, the company is moving beyond that constraint entirely. The keyword "infusion capacity" has since fallen sharply in prominence, replaced by "auto injector" and "number of prescribers" in the current quarter's top ranks.Back in February, Haruna noted that “after 18 months administration and then about 80% or over 80% of patients who have completed 18 months treatment wish to switch to the maintenance treatment.” — Katsuya Haruna, Head of US LEQEMBI Business · 2026-02-09 That stickiness is now being amplified by the subcutaneous option, which makes switching frictionless.The competitive dynamics are also shifting. Haruna noted that LEQEMBI has regained a leading share of new patient starts in the anti-amyloid therapy (AAT) market, and the gap versus competitors in total treated patients is widening. The disease progression benefit of long-term maintenance treatment is now better understood by physicians, and the flexibility to switch between IV and subcutaneous administration is pulling in previously reluctant prescribers—including rural physicians and general practitioners who lacked infusion infrastructure.Regarding IQLIK, IQLIK uptake has been very fast, particularly in the United States... Weekly sales of IQLIK has been shown to increase week after week, and we highly evaluate such continued increase in the sales.
The 2027 Medicare Part D Catalyst
Perhaps the most underappreciated near-term catalyst is the January 2027 inclusion of LEQEMBI in Medicare Part D formularies. Management disclosed that close to 70% of covered lives will have access at launch, with negotiations ongoing for the remainder. This is not just about reimbursement; it fundamentally changes the patient out-of-pocket calculus. Currently, under Medicare Part B, IV infusions are covered but require medical exception processes and can involve significant pocket cost for patients. Under Part D, out-of-pocket spending is capped at $2,100 annually, and 55% of IQLIK patients have already reached that cap, meaning zero out-of-pocket costs thereafter.“From January, because of the inclusion in formulary, we believe that there will be a further uptick, an increase in usage... out-of-pocket costs will decrease for patients once there is inclusion in formulary.” — Katsuya Haruna, Head of Global LEQEMBI Business · 2026-11-10The keyword Medicare Part D has been a recurring theme in Eisai's calls, but this is the first time management has provided concrete coverage percentages and a clear timeline. The setup mirrors the two-stage growth pattern Haruna outlined in February: first, the IQLIK launch drives adoption; then, formulary inclusion removes the final administrative and financial friction. Investors should watch for the remaining 30% of covered lives to be signed up through the first half of 2027, which could provide a second leg of upside.Guidance Conservatism and Pipeline Optionality
Despite the strong H1—revenue at 53.2% of full-year guidance and operating profit at 59.2%—management left the full-year forecast unchanged at JPY 70 billion operating profit. CFO Takuya Oyama cited "unpredictable uncertainties," specifically pointing to volume-based pricing (VBP) in China as a potential headwind. “As of today, quantitative uncertainty factors are not recognized by us yet. However, on the other hand, as far as we can recognize in China, impact of VBP, volume-based pricing, can bring about some impact, and that is being factored in to some extent.” — Takuya Oyama, Chief Financial Officer (CFO) · 2026-11-10 This conservatism is consistent with the company's history: in the February 2026 call, management also declined to raise guidance despite strong Q3 trends, citing structural reforms and R&D investments.The pipeline offers additional optionality. The DIAD cohort—dominantly inherited Alzheimer's disease—is being used in the DIAN TU ART study, where lecanemab is given for five years to asymptomatic mutation carriers. Positive data could support a filing for preclinical AD, expanding the label significantly earlier in the disease course. Separately, etalanetug (anti-MTBR tau antibody) is being studied in the Tau NexGen trial, with data expected in 2027. Ledasorexton, an orexin 2 receptor agonist for narcolepsy, achieved Phase II proof-of-concept and is being positioned as a potential blockbuster, with Phase II results for both NT1 and NT2 expected by March 2027.DIAN-TU ART using this cohort, amyloid removal trial is underway. Lecanemab will be given for 5 years to asymptomatic DIAD cohort. Results of the test are beginning to be obtained and the results are being expanded.